SEC Form 4 · accession 0001193125-26-256121
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Gannon
Director
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 9:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jun 1, 2026 | M | 2,645 | — | A | 13,286 | D | |
| Common SharesF2,F3 | Jun 1, 2026 | F | 1,416 | $53.41 | D | 11,870 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | — | Jun 1, 2026 | M | 2,645 | D | — | — | Common Shares | 2,645 | 0 | D |
| Share Option (Right to Buy)F4 | $53.46 | Jun 3, 2026 | A | 10,507 | A | — | Jun 2, 2036 | Common Shares | 10,507 | 10,507 | D |
| Restricted Share UnitsF5 | $0.00 | Jun 3, 2026 | A | 1,593 | A | — | — | Common Shares | 1,593 | 1,593 | D |
Explanation of responses
- F1Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
- F2Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale.
- F3Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations.
- F4Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
- F5Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.